Travere Therapeutics
TVTX
131 hedge funds and large institutions have $611M invested in Travere Therapeutics in 2019 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 47 increasing their positions, 43 reducing their positions, and 20 closing their positions.
18% more capital invested
Capital invested by funds: $516M → $611M (+$94.5M)
9% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 43
5% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 20
1% more funds holding
Funds holding: 130 → 131 (+1)
3.46% less ownership
Funds ownership: 103.6% → 100.14% (-3.5%)
74% less call options, than puts
Call options by funds: $668K | Put options by funds: $2.56M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$15.4M |
| 2 |
BlackRock
New York
|
+$5.16M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$4.96M |
| 4 |
D.E. Shaw & Co
New York
|
+$3.81M |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$3.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$20.2M |
| 2 |
SCM
Scopia Capital Management
New York
|
-$15.4M |
| 3 |
BC
Broadfin Capital
New York
|
-$7.08M |
| 4 |
State Street
Boston,
Massachusetts
|
-$5.3M |
| 5 |
PA
Perceptive Advisors
New York
|
-$4.85M |
TVTX Hedge Fund Activity: Q4 2019 in Review
131 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q4 2019, worth a combined $611M — up 18% from $516M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new TVTX positions and 20 closed out — a net gain of 1 holder — while 47 added to existing stakes and 43 trimmed.
The largest buyer was Millennium Management, adding an estimated $15.4M. The largest seller was Great Point Partners, exiting entirely with an estimated $20.2M sold.
- 131 institutional investors held Travere Therapeutics (TVTX) as of Q4 2019, up from 130 in Q3 2019.
- Funds reported $611M of Travere Therapeutics stock for Q4 2019, up 18% quarter-over-quarter.
- 21 funds opened new Travere Therapeutics positions in Q4 2019 and 20 closed out, a net change of +1 holder.
- The largest Travere Therapeutics buyer in Q4 2019 was Millennium Management, an estimated $15.4M added.
- The largest Travere Therapeutics seller in Q4 2019 was Great Point Partners, an estimated $20.2M sold.
Based on aggregated 13F filings for Q4 2019.